twoXAR Pharmaceuticals is now ARIA Pharmaceuticals. Read More

about us

ABOUT US

An aria is an elaborate, sophisticated section in an opera reserved for the top performer. Just as an aria boldly advances the plot, we are dedicated to advancing bold breakthroughs in medicine. At Aria Pharmaceuticals, we believe in the work we do for patients in need. Our name exhibits the artistry and complexity that defines how we approach medicine from idea to FDA approval in a way that is scientifically sound.

management

Andrew Radin

Combining his experience as an entrepreneur and technologist with his passion for social responsibility, Andrew co-founded Aria Pharmaceuticals to develop life-saving medicines to help treat patients in need. Prior to co-founding Aria, Andrew held Chief Technology Officer roles at several early-stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew developed the company’s proprietary platform and as Chief Executive Officer is focused on overall company strategy, product development and fundraising. Andrew studied biomedical informatics in Stanford University’s SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.

Mark Eller
Mark Eller brings 30 years of pharmaceutical R&D experience, including VP/SVP roles leading teams from discovery through approval. Mark’s previous experience encompasses both large (Quintiles, HMR/Sanofi predecessors) and small-to-midsize pharma companies (Jazz Pharmaceuticals) spanning a broad range of therapeutic areas. Mark has four FDA-approved drugs to his credit and is co-inventor on 30 patents. In addition he has led health authority presentations and negotiations, including six FDA advisory committee meetings. He has co-authored numerous scientific publications and served as an Adjunct Professor of Pharmaceutics at the University of Cincinnati. Mark received his Pharmacy degree and Ph.D. in Pharmaceutics from the University of Iowa.
ANJALI PANDEY
Anjali Pandey is an executive leader with 25+ years of experience in CSO/SVP roles through all stages of discovery through launch. Anjali previously served as SVP of Medicinal Chemistry & Chemical Development at Portola Pharmaceuticals, where she managed discovery and CMC for Bevyxxa™ and Cerdulatinib. Most recently, Anjali held CSO/EVP positions at BridgeBio Pharma subsidiaries TheRas and Ferro Therapeutics. Anjali has published over 45 scientific publications and is inventor on 60 issued U.S. patents. She holds an MS from the Indian Institute of Technology, a PhD from Southern Illinois University, and completed her postdoctoral fellowship at SRI International.
Aaron Daugherty

One of Aria Pharmaceuticals’ first employees, Aaron has helped build Aria’s drug discovery platform and leads the Discovery Science team’s efforts to discover potential treatments across a wide range of diseases. Aaron earned his PhD in Genetics from Stanford University. Prior to his time at Stanford, Aaron was a Fulbright Scholar and received his Bachelor of Science in Biology from the University of Richmond.

Brian Moriarty

Prior to joining Aria Pharmaceuticals, Brian held Vice President–level positions at leading technology companies including Hewlett-Packard and Sun Microsystems in the Finance, Human Resources, and Corporate Development functions. Prior to his work in industry, Brian advised clients as an investment banker. Throughout his deal-making career, Brian has closed more than 50 deals constituting more than $15 billion in transaction value. Brian holds an MBA from Kellogg School of Management at Northwestern University where he was awarded the F.C. Austin Scholarship and a BA from UC Davis where he majored in English and Economics.

board of directors

Scientific Advisory Board

BUSINESS ADVISORY BOARD